Charge variant and aggregation analysis of innovator and biosimilars of rituximab
27 Jun 2021Monoclonal antibodies are an important class of biomolecules used for the treatment of various diseases. Biosimilars, the copy versions of an innovator molecule, need to be characterized in detail for their critical quality attributes such as aggregates and charge variants. This application note compares two rituximab biosimilars from different manufacturers to the innovator for their aggregation and charge variant profiles by following two analytical workflows using Agilent 1260 Infinity II Bio-Inert LC and Agilent AdvancedBio columns.
Related Products
Request Quote for All Products
Agilent 1260 Infinity II Bio-Inert LC System
Agilent TechnologiesThe 1260 Infinity II Bio-Inert LC is a dedicated solution for analysis of large biomolecules in biological samples, including monoclonal antibody (mAb) and protein analysis. Metal-free components in the sample flow path and the absence of iron and steel in solvent delivery lines ensure the integrity of your biomolecules, minimize unwanted surface interactions, and increase column lifetime.
AdvanceBio HIC
Agilent TechnologiesAgilent AdvanceBio HIC columns deliver robust and reproducible high-resolution separations of native proteins at the intact level.